VALN News and Press, Valneva SE From 06/21/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Joseph GTK / Shutterstock.com Advanced Micro Devices (NASDAQ: AMD ) stock is rising higher on Tuesday after announcing a new generation of processors . Let’s go over all the details investors n...

Gainers: Convey Health Solutions CNVY +139%. Valneva  VALN +87%. Clovis Oncology (CLVS) +34%. Innate Pharma (IPHA) +28%. Lexaria Bioscience (LEXX) +20%. Losers: ACADIA Pharmaceuticals ACAD -34%. Comera Life Sciences Holdings (CMRA) -17%. ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Manuel Esteban / Shutterstock.com Valneva (NASDAQ: VALN ) stock is rocketing higher on Tuesday following news that Pfizer (NYSE: PFE ) is taking a stake in the vaccine company . Pfizer has reach...

The ADRs of Valneva (NASDAQ:VALN) added ~86% in the pre-market Tuesday as the French vaccine maker extended gains following an equity investment from U.S. pharma giant Pfizer (PFE) as part of their collaboration for a vaccine against Lyme Disease. Per the terms, Pfizer (PFE) bo...

Valneva (VALN) (OTCPK:INRLF) rose in the Paris stock exchange on Monday in reaction an agreement under which Pfizer (NYSE:PFE) will purchase 8.1% stake in the French vaccine maker to further support the partnership between the two companies for a vaccine against Lyme Disease. In 2020, Valneva...

Pfizer will invest €90.5 million in Valneva Planned Phase 3 study confirmed to initiate in Q3 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced that they have enter...

Valneva (NASDAQ:VALN -9.8%) entered into a settlement agreement with the Government of the United Kingdom in relation to the termination of the supply agreement for Valneva’s COVID-19 vaccine candidate, VLA2001. Company announced on September 13, 2021 that it had receive...

The ADRs of Valneva SE (NASDAQ:VALN) dropped for the third straight session on Monday after the French vaccine maker said that its deal with European Commission for an experimental COVID-19 shot hangs in the balance. The whole virus, inactivated vaccine candidate, named VLA2001, is designed t...

Valneva (NASDAQ:VALN) said it successfully completed a lot-to-lot phase 3 trial of its single-shot chikungunya vaccine VLA1553. The company said the final analysis included six-month follow-up data and confirmed the results reported in December 2021, where the trial met its main goal. "W...

Several days after experiencing a pleasant share price pop on good regulatory news, Dynavax (NASDAQ: DVAX) repeated the feat on Thursday. An important partner for the company reported an encouraging development that morning, also in the regulatory sphere. Investors lapped up the fre...